ArticleTheranostics2019
CD4
Article in Theranostics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 2 syntheses or guidelines pooled it, 105 citations in OpenAlex.
- The Future of Cancer Diagnosis, Treatment and Surveillance: A Systemic Review on Immunotherapy and Immuno-PET Radiotracers.Molecules (Basel, Switzerland) · 2021Pooled it
- Poor Lymphocyte Infiltration to Primary Tumors in Acral Lentiginous Melanoma and Mucosal Melanoma Compared to Cutaneous Melanoma.Frontiers in oncology · 2020Pooled it
- Targeted Photo-Induced Elimination of Tumor-Associated Macrophages Suppresses Cancer Progression in a Murine Model.Cancer science · 2026Article
- Cancer cells accelerate exhaustion of persistently activated mouse CD4Oncoimmunology · 2025Article
- Precise combination therapy of radiotherapy and immunotherapy guided by joint PD-L1 imaging and T-cell imaging.Journal for immunotherapy of cancer · 2025Article
- Long Axial Field of View PET: A New Era of Quantitative PET Imaging for Prospective Applications Beyond Classical Theranostics.PET clinics · 2025Review
- PET Imaging of Diabetes-Induced Alterations in Metabolism and Immune Activation.Molecular imaging and biology · 2025Article
- Review
- PET-based immunomapping of intratumoral CD4Science advances · 2025Article
- Identifying effective immune biomarkers in alopecia areata diagnosis based on machine learning methods.BMC medical informatics and decision making · 2025Article
- The regulatory role of immune microenvironment-related cells and pathways in the pathogenesis of keloids.Frontiers in immunology · 2025Review
- Using NGS to Uncover the Corruption of a Peptide Phage Display Selection.Current issues in molecular biology · 2024Article
- PD-L1 siRNA hitched polyethyleneimine-elastase constituting nanovesicle induces tumor immunogenicity and PD-L1 silencing for synergistic antitumor immunotherapy.Journal of nanobiotechnology · 2024Article
- Evaluating the immunologically "cold" tumor microenvironment after treatment with immune checkpoint inhibitors utilizing PET imaging of CD4 + and CD8 + T cells in breast cancer mouse models.Breast cancer research : BCR · 2024Article
- Article
- Illuminating immunotherapy response via precision T cell-targeted PET imaging.Frontiers in medicine · 2024Review
- The role of CD8 PET imaging in guiding cancer immunotherapy.Frontiers in immunology · 2024Review
- In-depth cross-validation of human and mouse CD4-specific minibodies for noninvasive PET imaging of CD4Theranostics · 2024Article
- Review
- Development of [EJNMMI research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Predicting the outcome of immunotherapy is essential for efficient treatment. The recent clinical success of immunotherapy is increasingly changing the paradigm of cancer treatment. Accordingly, the development of immune-based agents is accelerating and the number of agents in the global immuno-oncology pipeline has grown 60-70% over the past year. However, despite remarkable clinical efficacy in some patients, only few achieve a lasting clinical response. Treatment failure can be attributed to poorly immunogenic tumors that do not attract tumor infiltrating lymphocytes (TILs). Therefore, we developed positron emission tomography (PET) radiotracers for non-invasive detection of CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.